Updates in Oncology
I costi elevati dei farmaci, soprattutto quelli oncologici, impongono scelte. Gran Gretagna: le decisioni di NICE & CDF [ Cancer Drugs Fund ]
–
Il Servizio sanitario inglese, NHS, ha aumentato il budget per il comparto farmaci antitumorali da 280 milioni di sterline nel…
Il NICE ( National Institute for Health and Care Excellence ) ha aperto una consultazione sulla bozza di determinazione riguardante…
Focus On: inibitori PD-1 nel carcinoma polmonare non-a-piccole cellule squamoso metastatico
L’Agenzia regolatoria degli Stati Uniti, FDA ( Food and Drug Administration ) ha approvato Opdivo ( Nivolumab ), un inibitore PD-1, nel trattamento del tumore al polmone non-a-piccole cellule ( NSCLC …
Nivolumab ( Opdivo ) ha prodotto risposte durature e prolungata sopravvivenza globale nei pazienti con cancro del polmone non-a-piccole cellule, trattato in precedenza.
FDA / Melanoma in fase avanzata
Bristol-Myers Squibb ( BMS ) ha annunciato che la FDA ( Food and Drug Administration ) ha accettato la domanda di registrazione supplementare ( supplemental Biologics License Application; sBLA ) per i …
OncoDigest
Diagnostics
A new study has provided the first evidence that the mediator complex subunit 15 ( MED15 ) may play a crucial role in the pathophysiology of head and neck squamous cell carcinoma ( HNSCC ). MED15 ov …
Surgery
In a study, researchers from Brigham and Women’s Hospital ( BWH ) ( Boston, Massachusetts; USA ) have reported that breast surgery performed at or shortly after a diagnosis of low-grade ductal carcino …
Therapy
A review, titled Immune Checkpoint Targeting in Cancer Therapy: Toward Combination Strategies with Curative Potential, from researchers at The University of Texas MD Anderson Cancer Center published i ..
The application was for Regorafenib ( Stivarga ) to remain in the Cancer Drugs Fund ( CDF ) as treatment for patients with non-resectable or metastatic gastrointestinal stromal tumours ( GISTs ) who w …
Cancer Drugs Fund ( CDF ) Panel has assessed the application was for single agent Pemetrexed ( Alimta ) to remain in the CDF as maintenance treatment for patients with locally advanced or metastatic …
Cancer Drugs Fund ( CDF ) Panel has assessed the application for Eribulin ( Halaven ) to remain in the CDF list as 3rd line chemotherapy for patients with locally advanced or metastatic breast c …
Cancer Drugs Fund ( CDF ) Panel has assessed the application for single agent Pemetrexed ( Alimta ) to remain in the CDF as 2nd line treatment for patients with non-squamous ( NS ) non-small cell lun …
National Institute for Health and Care Excellence ( NICE ) in the UK, has recommended Vargatef ( Nintedanib ) in combination with Docetaxel for use within the National Health Service ( NHS ) in Englan …
Cancer immunotherapy
Nivolumab ( Opdivo ) is a programmed death-1 ( PD-1 ) immune checkpoint inhibitor which has shown durable tumor responses in multiple cancer types and prolongs overall survival in patients with melano …
Programmed death-1 ( PD-1 ) is a co-inhibitory receptor expressed on activated T cells which regulates antitumor immunity. Nivolumab ( Opdivo ) is a fully-humanized IgG4 that blocks the engagement o …
Brain metastases develop in 40% of metastatic melanoma patients. Untreated brain metastases exclude from most clinical trials. In prior trials, treatment of metastatic melanoma with Pembrolizumab ( Ke …
Outcomes are poor for patients with recurrent / metastatic squamous cell carcinoma of the head and neck ( SCCHN ), and new treatments are needed. An ongoing phase I/II, multicenter, open-label study …
PD-1 antibody, Nivolumab ( Opdivo ), was administered with/without a multi-peptide vaccine to 126 patients ( pts ) with unresectable melanoma that failed at least one regimen and were Ipilimumab ( Yer …
Anti-PD-1 therapy has shown significant clinical activity in advanced melanoma and in other cancers. Factors predictive of response remain vaguely defined. Researchers have reported on clinical ch …